Regeneron Pharmaceuticals | REGN

Stock Price
674.92
Daily Change
2.74 0.41%
Monthly
10.19%
Yearly
20.32%
Q3 Forecast
662.48

EPS Reference Time Actual Consensus Previous
2026-10-29 FY2026Q3 AM 13.04 11.83
2026-07-30 FY2026Q2 AM 10.85 12.89
2026-04-29 FY2026Q1 AM 9.47 9.13 8.22
2026-01-30 FY2025Q4 AM 11.44 10.61 12.07
2025-10-28 FY2025Q3 AM 11.83 9.67 12.46



Peers Price Chg Day Year Date
Kyowa Hakko Kirin 2,628.50 -20.50 -0.77% 6.03% Jul/22
Astellas Pharma 2,172.00 -24.50 -1.12% 52.64% Jul/22
AbbVie 256.13 2.75 1.09% 36.89% Jul/21
Agenus 5.39 0.42 8.45% -11.49% Jul/21
Agios Pharmaceuticals 38.59 -1.47 -3.67% -3.53% Jul/21
Alnylam Pharmaceuticals 272.71 0.04 0.01% -16.16% Jul/21
Amgen 362.45 -1.72 -0.47% 18.57% Jul/21
AstraZeneca 12,492.00 112.00 0.90% 20.67% Jul/21
Biogen 202.74 2.79 1.40% 58.58% Jul/21
BioMarin Pharmaceutical 59.28 0.17 0.29% 0.14% Jul/21

Indexes Price Day Year Date
US500 7502 65.92 0.89% 17.98% Jul/22
USND 25837 329.13 1.29% 23.67% Jul/21
US100 28937 550.95 1.93% 24.93% Jul/22

Regeneron Pharmaceuticals traded at $674.92 this Tuesday July 21st, increasing $2.74 or 0.41 percent since the previous trading session. Looking back, over the last four weeks, Regeneron Pharmaceuticals gained 10.19 percent. Over the last 12 months, its price rose by 20.32 percent. Looking ahead, we forecast Regeneron Pharmaceuticals to be priced at 662.48 by the end of this quarter and at 621.61 in one year, according to Trading Economics global macro models projections and analysts expectations.

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious diseases. The Company commercializes medicines and product candidates for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases, and rare diseases. The Company's marketed products include EYLEA (aflibercept) Injection, Dupixent (dupilumab) Injection, Libtayo (cemiplimab) Injection, Praluent (alirocumab) Injection, Kevzara (sarilumab) Solution for Subcutaneous Injection, Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use and ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion.